PADI1 and PADI3 promote resistance to KRAS inhibitors by sustaining mitochondrial adaptation in KRAS-driven tumors.
- Open access
Moving in bioRxiv, Blood, Cell Reports, Frontiers in Genetics, Molecular Cell, Plant Physiology and Biochemistry.
Rebuilt
Nothing in this area has moved yet this week.
Newest first · last 60 days
PADI1 and PADI3 promote resistance to KRAS inhibitors by sustaining mitochondrial adaptation in KRAS-driven tumors.
In PTPN11-mutant juvenile myelomonocytic leukemia, dual NLRP3 and PTGS2 inhibition combined with MEK blockade significantly prolongs survival and reduces leukemic burden in models.
Loss of FAP-1 causes defective megakaryocyte membrane development, impaired platelet function, and myelofibrosis-like features in mice, with 50% developing severe symptoms.
A de novo 15q11.1-q13.3 duplication with tetrasomy and trisomy was linked to severe neurodevelopmental delays and autism in a girl, expanding known genomic variations.
NtA motif-driven asymmetric BRAF dimerization activates MEK1 phosphorylation, revealing a structural basis for BRAF's role in cancer signaling.
Journals this month
Moving areas, week to 3 Oct 2026